LETTER TO THE EDITOR
Comment on: Kikuchi–Fujimoto disease following SARS-CoV-2 vaccination in a patient with previous history of rhabdomyosarcoma
Amnuay Kleebayoon,
Corresponding Author
Amnuay Kleebayoon
Private Academic Consultant, Samraong, Cambodia
Correspondence
Amnuay Kleebayoon, Samraong, Cambodia.
Email: [email protected]
Search for more papers by this author Viroj Wiwanitkit,
Viroj Wiwanitkit
Research Center, Chandigarh University, Chandigarh, Punjab, India
Joesph Ayobabalola University, Ikeji-Arakeji, Nigeria
Search for more papers by this author
Amnuay Kleebayoon,
Corresponding Author
Amnuay Kleebayoon
Private Academic Consultant, Samraong, Cambodia
Correspondence
Amnuay Kleebayoon, Samraong, Cambodia.
Email: [email protected]
Search for more papers by this author Viroj Wiwanitkit,
Viroj Wiwanitkit
Research Center, Chandigarh University, Chandigarh, Punjab, India
Joesph Ayobabalola University, Ikeji-Arakeji, Nigeria
Search for more papers by this author
First published: 09 May 2023
No abstract is available for this article.
REFERENCES
- 1Sevrin F, Beaujot J, Jaillard A, Fayard C, Forestier A, Defachelles AS. Kikuchi–Fujimoto disease following SARS-CoV-2 vaccination in a patient with previous history of rhabdomyosarcoma. Pediatr Blood Cancer. 2023; 70:e30345. doi:10.1002/pbc.30345
- 2Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost. 2021; 27:10760296211047229.
- 3Joob B, Wiwanitkit V. Letter to the Editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020; 53(2): 70.
- 4Čiučiulkaitė I, Möhlendick B, Thümmler L, et al. GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022; 13:932043.
